sever
acut
respiratori
syndrom
sar
rais
global
alert
sinc
march
caus
agent
sarsassoci
coronaviru
sarscov
confirm
laboratori
method
includ
viru
isol
revers
transcriptasepolymeras
chain
reaction
rtpcr
serolog
method
quickli
develop
studi
evalu
four
serolog
test
neutral
test
enzymelink
immunosorb
assay
elisa
immunofluoresc
assay
ifa
immunochromatograph
test
ict
detect
antibodi
sarscov
sera
probabl
sar
casepati
correl
rtpcr
neutral
test
refer
method
sensit
specif
posit
predict
valu
neg
predict
valu
elisa
ifa
ict
respect
also
compar
recombinantbas
western
blot
whole
virusbas
ifa
elisa
data
show
high
correl
method
overal
agreement
result
provid
systemat
analysi
serolog
molecular
method
evalu
sarscov
infect
sar
quickli
identifi
new
coronaviru
speci
refer
sarsassoci
coronaviru
sarscov
epidemiolog
evid
droplet
close
contact
transmiss
major
rout
spread
sar
suspect
sar
patient
need
quarantin
treat
intens
care
minim
transmiss
other
therefor
sensit
specif
laboratori
test
differenti
sar
mild
atyp
pneumonia
must
develop
shorten
quarantin
period
contact
sar
patient
contain
sar
outbreak
even
though
rtpcr
sensit
techniqu
detect
earli
sarscov
infect
posit
predict
rate
probabl
sar
case
accord
data
center
diseas
controltaiwan
report
probabl
sar
case
therefor
still
reli
serolog
diagnosi
analyz
result
immunofluoresc
assay
ifa
enzymelink
immunosorb
assay
elisa
neutral
test
immunochromatograph
test
ict
detect
antibodi
sarscov
serum
specimen
patient
probabl
sar
taiwan
result
neutral
test
elisa
ifa
highli
correl
accord
world
health
organ
criteria
person
seek
treatment
novemb
histori
high
fever
cough
breath
difficulti
resid
travel
area
recent
local
transmiss
sar
day
onset
symptom
classifi
suspect
casepati
suspect
casepati
radiograph
evid
infiltr
consist
pneumonia
respiratori
distress
syndrom
chest
xray
consid
method
sarsassoci
coronaviru
infect
taiwan
probabl
casepati
studi
throat
swab
specimen
possibl
sar
patient
report
center
diseas
controltaiwan
test
sarscov
rtpcr
seven
hundr
ninetynin
serum
sampl
probabl
casepati
fulfil
criteria
probabl
sar
case
test
antibodi
sarscov
neutral
test
ifa
elisa
ict
patient
pair
serum
specimen
acuteand
convalescentphas
serum
specimen
collect
day
day
day
onset
ill
respect
patient
singl
serum
specimen
collect
ill
serum
collect
acut
phase
earli
convalesc
phase
day
day
collect
late
convalesc
phase
day
day
ill
onset
primer
probe
use
sarscov
detect
rtpcr
realtim
rtpcr
synthes
accord
recommend
center
diseas
control
prevent
cdc
atlanta
georgia
usa
viral
rna
throat
swab
specimen
extract
magna
lc
pure
magna
pure
lc
total
nucleic
acid
isol
kit
rouch
mannheim
germani
extract
rna
extract
use
templat
pcr
assay
reaction
volum
contain
buffer
enzym
mix
deoxynucleosid
triphosph
dntp
sens
antisens
primer
reaction
subject
precycl
condit
min
min
forti
cycl
amplif
conduct
min
realtim
quantit
rtpcr
assay
reaction
volum
contain
hpa
human
pneumoniaassoci
coronaviru
coronaviru
lc
master
mix
hpacoronaviru
lc
mgsol
hpacoronaviru
lc
intern
control
thermalcycl
light
cycler
rouch
min
rt
reaction
min
denatur
follow
cycl
amplif
serum
specimen
test
neutral
activ
accord
procedur
describ
marx
et
al
modif
neutral
titer
determin
vero
cell
briefli
serum
specimen
patient
probabl
sar
first
incub
min
serial
twofold
dilut
serum
specimen
ad
equal
volum
cultur
medium
contain
sarscov
tissu
cultur
infect
dose
tcid
microtit
plate
incub
h
final
vero
cell
x
ad
well
plate
cultur
held
co
daili
observ
cytopath
effect
cpe
day
titer
antibodi
calcul
highest
dilut
cpe
complet
inhibit
well
neutral
test
carri
sampl
duplic
along
posit
neg
control
posit
control
serum
specimen
taken
patient
confirm
sar
taiwan
neg
control
serum
specimen
healthi
volunt
sampl
show
differ
greater
titer
duplic
sampl
run
judg
invalid
outcom
retest
sampl
consid
posit
titer
case
singl
serum
group
least
increas
titer
acuteand
convalescentphas
serum
specimen
pair
specimen
group
ifa
test
perform
use
dilut
serum
specimen
react
sarscovinfect
vero
cell
uninfect
vero
cell
vero
cell
grown
minimum
essenti
medium
mem
contain
fetal
bovin
serum
densiti
cell
infect
sarscov
tcid
ml
cpe
appear
cell
wash
trypsin
spot
slide
ifa
previous
describ
slide
put
close
heat
contain
complet
dri
fix
aceton
min
serial
dilut
serum
start
place
onto
well
slide
incub
min
wash
twice
phosphatebuff
salin
pb
min
dilut
specif
antihuman
gamma
globulin
label
fitc
zyme
ad
onto
well
incub
min
wash
twice
pb
slide
observ
fluoresc
microscop
criteria
posit
ifa
result
includ
reactiv
infect
cell
sampl
antibodi
titer
posit
sera
react
infect
cell
consid
neg
nonspecif
reactiv
infect
uninfect
cell
detect
test
consid
uninterpret
elisa
detect
coronaviru
describ
studi
materi
elisa
detect
sarscov
antibodi
provid
cdc
atlanta
brief
sarscov
vero
cell
lysat
use
antigen
ad
top
half
well
plate
overnight
vero
cell
lysat
without
sarscov
use
control
antigen
simultan
ad
well
bottom
half
plate
follow
day
dilut
serum
start
ad
test
control
well
well
plate
incub
min
wash
plate
time
wash
buffer
well
add
conjug
dilut
goat
antihuman
immunoglobulin
ig
igg
igm
well
incub
plate
min
wash
substrat
mixtur
sulfon
acid
abt
hydrogen
peroxid
ad
well
incub
min
place
plate
elisa
reader
read
nm
sampl
posit
adjust
optic
densiti
od
valu
od
test
od
control
exce
mean
plu
standard
deviat
normal
control
titer
ict
gener
refer
rapid
chromatograph
techniqu
base
sandwich
format
use
doubl
antigen
doubl
antibodi
sarscov
rapid
test
adopt
newli
develop
immunogoldbas
ict
devic
tyson
bioresearch
inc
taipei
taiwan
antigen
use
test
recombin
nucleocapsid
n
protein
sarscov
insid
ict
devic
contain
nitrocellulos
strip
top
detect
zone
detect
zone
goat
antimous
igg
sarscov
n
protein
immobil
separ
onto
control
line
test
line
middl
strip
mous
igg
sarscov
n
protein
coupl
respect
colloid
gold
particl
serv
detector
bottom
two
well
sampl
buffer
respect
ict
carri
follow
manufactur
instruct
briefli
undilut
serum
sampl
ad
sampl
well
test
buffer
buffer
well
sampl
contain
specif
antibodi
sarscov
react
first
antigengold
complex
later
flow
along
membran
color
complex
antibodiesantigengold
deposit
test
line
contain
fix
antigen
red
signal
gold
gradual
appear
test
line
becom
visibl
nake
eye
posit
result
show
two
parallel
line
upper
one
control
line
show
devic
work
fine
lower
one
test
line
indic
serum
sampl
contain
sarscov
antibodi
case
neg
result
red
seen
control
line
red
found
test
line
line
visibl
test
invalid
prepar
recombin
protein
sarscov
procedur
western
blot
assay
describ
recent
briefli
amplifi
gene
product
sarscov
includ
n
membran
spike
gel
purifi
clone
express
vector
qiagen
valancia
ca
construct
transform
escherichia
coli
cell
invitrogen
carlsbad
ca
induct
cell
sonic
recombin
protein
extract
sarcosin
final
recombin
protein
bound
bd
talon
metal
affin
resin
bd
bioscienc
san
jose
ca
examin
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
western
blot
assay
carri
examin
pattern
antibodi
develop
differ
recombin
protein
sarscov
total
possibl
sar
patient
report
center
diseas
controltaiwan
march
end
juli
probabl
casepati
suspect
casepati
reject
casepati
remov
report
tabl
throat
swab
collect
patient
probabl
case
posit
result
pcr
give
posit
rate
throat
swab
also
collect
patient
suspect
case
posit
result
pcr
give
posit
rate
figur
show
pcrposit
rate
throat
swab
specimen
taken
patient
probabl
sar
day
day
ill
onset
first
day
onset
rtpcr
detect
posit
result
patient
suspect
case
posit
rate
reach
peak
day
day
declin
thereaft
howev
specimen
viru
rna
still
detect
day
day
day
ill
onset
data
shown
figur
show
antibodi
sarscov
appear
infect
although
sampl
probabl
casepati
antibodi
sarscov
could
detect
acut
phase
ill
day
day
neutral
test
ifa
elisa
antibodi
sarscov
develop
late
convalesc
stage
posit
rate
antibodi
sarscov
rais
week
ill
onset
reach
peak
week
onset
overal
antibodyposit
rate
total
probabl
sar
casepati
test
antibodi
respons
sarscov
neutral
test
elisa
ifa
parallel
patient
test
ict
neutral
test
refer
method
overal
characterist
evalu
method
includ
elisa
ifa
ict
given
tabl
elisa
sensit
measur
serum
specimen
test
posit
neutral
test
gave
neg
respons
elisa
specif
posit
predict
valu
neg
predict
valu
respect
ifa
sensit
evalu
two
serum
sampl
posit
neutral
test
neg
ifa
specif
posit
predict
valu
neg
predict
valu
respect
specif
ict
calcul
howev
sensit
low
lead
neg
predict
valu
total
neg
neutral
test
posit
result
detect
elisa
posit
ifa
posit
ict
test
specimen
taken
patient
two
posit
pcr
result
found
ten
normal
serum
sampl
healthi
volunt
test
neg
antibodi
sarscov
neutral
test
ifa
elisa
ict
addit
serum
sampl
patient
diseas
use
specif
panel
analyz
whether
assay
show
cross
reaction
sarscov
patient
definit
confirm
nonsarscovassoci
diseas
shown
tabl
posit
result
detect
serum
specimen
measur
specif
neutral
test
elisa
ifa
ict
tabl
compar
result
rtpcr
neutral
test
specimen
probabl
sar
casepati
comparison
throat
swab
specimen
probabl
sar
casepati
use
rtpcr
convalescentphas
serum
specimen
collect
day
longer
ill
onset
test
neutral
test
case
posit
neutral
test
test
posit
rtpcr
sensit
specif
posit
predict
valu
neg
predict
valu
rtpcr
compar
result
neutral
test
respect
discuss
neutral
test
elisa
ifa
base
whole
viral
extract
sarscov
therefor
antigen
serolog
test
must
prepar
biosafeti
level
laboratori
provid
conveni
tool
decreas
risk
infect
western
blot
sever
sarscov
recombin
protein
develop
evalu
clone
peptid
carri
epitop
produc
larg
scale
accept
degre
puriti
tabl
show
comparison
recombin
proteinbas
western
blot
whole
virusbas
ifa
elisa
ninetyf
serum
sampl
use
comparison
sensit
specif
overal
agreement
western
blot
compar
ifa
result
compar
elisa
result
studi
show
first
period
onset
sar
rtpcr
sensit
method
detect
viru
rna
posit
rate
highest
howev
convalesc
phase
diseas
detect
antibodi
serum
specimen
import
detect
viral
rna
four
serolog
diagnost
method
includ
neutral
test
elisa
ifa
ict
evalu
compar
antibodi
respons
sarscov
infect
neutral
test
held
refer
method
specif
method
extrem
good
sinc
crossreact
detect
nonsar
diseas
panel
howev
variat
sensit
posit
predict
valu
neg
predict
valu
found
among
method
shown
tabl
elisa
result
highli
correl
result
refer
method
neutral
test
measur
perform
elisa
outstand
sensit
specif
posit
predict
valu
neg
predict
valu
level
exceed
elisa
chosen
confirm
altern
case
ifa
sensit
neg
predict
valu
level
howev
specif
impli
ifa
may
caus
falseposit
problem
therefor
weak
posit
ifa
result
retest
neutral
test
elisa
ict
though
simpl
quick
perform
lack
adequ
sensit
evalu
therefor
reliabl
test
detect
antibodi
sarscov
sinc
neutral
test
elisa
ifa
use
whole
viru
particl
antigen
safeti
reason
prepar
sarscov
antigen
must
conduct
biosafeti
level
laboratori
prevent
test
method
wide
appli
therefor
trend
method
develop
may
lead
toward
manufactur
antigen
certain
recombin
protein
studi
compar
recombinantbas
western
blot
whole
virusbas
ifa
elisa
data
show
high
degre
correl
method
overal
agreement
tabl
thu
use
recombin
antigen
may
becom
much
safer
altern
detect
antibodi
sarscov
eight
pcrposit
specimen
found
group
rule
group
report
cancel
tabl
select
test
antibodi
sarscov
use
acutephas
serum
sampl
day
day
ill
onset
howev
posit
result
found
ifa
elisa
neutral
test
sinc
convalescentphas
serum
specimen
collect
patient
know
neg
result
truli
neg
result
time
gather
specimen
antibodi
produc
moreov
anoth
sampl
ruledout
categori
test
elisa
posit
result
found
addit
specimen
casepati
suspect
sar
also
assay
elisa
neutral
test
posit
posit
rate
among
pcrposit
specimen
suspect
sar
categori
also
posit
detect
antibodi
sarscov
final
studi
overal
antibodi
posit
rate
probabl
sar
patient
rate
much
lower
report
hong
kong
show
igg
seroconvers
sar
coronaviru
high
day
ill
onset
differ
may
come
differ
circumst
hong
kong
taiwan
sar
outbreak
hong
kong
index
casepati
infecti
sourc
lead
outbreak
quit
clear
patient
admit
hospit
within
day
epidemiolog
point
view
therefor
sar
outbreak
typic
cluster
outbreak
taiwan
sampl
probabl
sar
casepati
collect
hospit
march
june
might
true
sar
patient
report
probabl
sar
case
result
serum
specimen
day
ill
onset
probabl
sar
casepati
test
comparison
new
classif
posit
rate
antibodi
sarscov
probabl
sar
patient
taiwan
increas
use
serum
sampl
day
beyond
onset
ill
rate
closer
though
still
lower
rate
hong
kong
sampl
remain
case
exclud
categori
probabl
sar
case
may
test
pathogen
mycoplasma
pneumonia
chlamydia
pneumonia
human
metapneumoviru
clarifi
diagnosi
